BioSpace News Archive

Vigil Health Solutions Inc. (“Vigil”) (TSX-V: VGL), is pleased to announce that, at its 2020 AGM shareholders elected Troy Griffiths, Greg Peet, Ian Power and Lindsay Ryerson as Directors of Vigil.

Fluidigm Corporation announced it has received Emergency Use Authorization from the U.S. Food and Drug Administration for the Advanta™ Dx SARS-CoV-2 RT-PCR Assay, an extraction-free saliva-based test to detect nucleic acid from the SARS‑CoV‑2 virus, designed to be run on the Fluidigm® Biomark™ HD microfluidics platform.

Amylyx Pharmaceuticals, Inc., a pharmaceutical company focused on developing new treatments for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the appointment of Tammy Sarnelli as Global Head of Regulatory Affairs.

ADA Leads 20 National Patient Advocate Groups Urging USPS Delivery Improvements

Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company powering continuous delivery of approved drugs for novel indications, announced today that Cidnee Vaykovich has been appointed Chief Operating Officer, effective immediately. “We continue to strengthen our management team in order to successfully position the Company for future growth,” said Pedro Lichtinger, Chief Executive Officer. “Cidnee brings a brea

Hologic, Inc. (Nasdaq: HOLX), a global leader in women’s health, announced today that it has acquired Acessa Health Inc., a privately-held innovator in minimally invasive treatment for fibroids, for approximately $80 million in cash plus contingent payments based on future revenue growth.

CohBar, Inc. (NASDAQ: CWBR) (the “Company”), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced a proposed underwritten public offering of units consisting of one share of the Company’s common stock and one warrant to purchase 0.75 of a share of common stock. Each warrant will be exercisable for five years from the closing date of the offer

TransEnterix, Inc. (NYSE American: TRXC), a medical device company that is digitizing the interface between the surgeon and the patient to improve minimally invasive surgery, today announced that in connection with the appointment of Shameze Rampertab as the Company’s Executive Vice President and Chief Financial Officer effective August 24, 2020,

HitGen Inc. (688222.SH) announced that the company has achieved a milestone in their strategic collaboration with Almirall to develop a novel class of drugs

Rafarma Pharmaceuticals, Inc. “OTC:” is pleased to announce that it has established a new corporate entity in Thailand.